Sponsors (12)
The bill channels focused federal research support toward children with DIPG and their families—offering hope for better treatments and trials—while requiring public funds and risking reduced resources for other medical research priorities.
Children with DIPG would receive increased federal research funding focused on developing treatments and improving survival.
Families and caregivers would likely benefit from accelerated clinical trials and expanded pediatric oncology resources driven by the targeted research investment.
Taxpayers could face modestly higher federal research spending if appropriations increase to support DIPG research.
Prioritizing DIPG funding may divert limited research dollars away from other pediatric cancers, rare diseases, or chronic-condition research, potentially delaying progress for those patients.
Based on analysis of 2 sections of legislative text.
Finds DIPG is a severe pediatric brain cancer with very poor survival and states federal pediatric cancer research funding should be increased.
Official title: Expressing support for the designation of May 17, 2025, as "DIPG Awareness Day" to raise awareness and encourage research into cures for diffuse intrinsic pontine glioma (DIPG) and pediatric cancers in general.
Introduced May 15, 2025 by Debbie Dingell · Last progress May 15, 2025
Directs attention to diffuse intrinsic pontine glioma (DIPG), a rare but deadly childhood brain tumor with very poor survival that has seen little improvement in decades, and states that federal pediatric cancer research funding should be increased to address unmet needs. The resolution summarizes DIPG incidence, survival statistics, and the estimated person-years of life lost, and calls for greater federal research support to improve outcomes for affected children and families.